YU49060B - FARMACEUTSKE KOMPOZICIJE KOJE SADRŽE INHIBITOR BIOSINTEZE HOLESTEROLA I INHIBITIR APSORPCIJE Гџ-LAKTAM HOLESTEROLA - Google Patents
FARMACEUTSKE KOMPOZICIJE KOJE SADRŽE INHIBITOR BIOSINTEZE HOLESTEROLA I INHIBITIR APSORPCIJE Гџ-LAKTAM HOLESTEROLAInfo
- Publication number
- YU49060B YU49060B YU80293A YU80293A YU49060B YU 49060 B YU49060 B YU 49060B YU 80293 A YU80293 A YU 80293A YU 80293 A YU80293 A YU 80293A YU 49060 B YU49060 B YU 49060B
- Authority
- YU
- Yugoslavia
- Prior art keywords
- cholesterol
- inhibitor
- pct
- lactam
- absorpcion
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Hematology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Diabetes (AREA)
- Vascular Medicine (AREA)
- Obesity (AREA)
- Urology & Nephrology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Cosmetics (AREA)
Abstract
Farmaceutska kompozicija za lecenje ili sprecavanje ateroskleroze ili za smanjenje nivoa holesterola u plazmi, koja sadrzi jedan inhibitor apsorpcije ß-laktam holesterola, jedan inhibitor HMG CoA reduktaze i farmaceutski prihvatljiv nosac, naznacena time, sto je inhibitor apsorpcije ß-laktam holesterola predstavljen strukturnom formulom: gde je: A, -CH=-CH-B; -C=C-B; -(CH2)p-X-B, gde je p, 0, 1 ili 2 i X je veza, -NH-ili -S(O)0-2; heteroaril, benzokondenzovani heteroaril, W-supstisuisani heteroaril ili W-supstituisani benzokondenzovani heteroaril, gde je heteroaril odabran iz grupe koju cine: pirolil, piridinil, pirimidinil, pirazinil, triazinil, imidazolil, tiazolil, pirazolil, tienil, oksazolil i furanil, a za heteroarile sa azotom, wihove N-okside i gde W cine 1-3 supstituenta na ugljenikovom atomu prstena odabrani iz grupe koju cine nizi alkil, hidroksi nizi alkil, nizi alkoksi, alkoksialkil, akoksialkoksi, alkoksikarbonilalkoksi, (nizi alkoksi imino) nizi alkil, nizi alkandioil, nizi alkil nizi alkandioil, aliloksi, -CF3, -OCF3, benzil, R14-benzil, benziloksi, R14-benziloksi, fenoksi, R14-fenoksi dioksolanil, NO2, - NR10R11, NR10R11(nizi alkil)-, NR10R11(nizi alkoksi)-, OH, halogeno, -NHC(O)OR5 ,-NHC(O)R5, R6O2SNH-, (R6O2S)2N-, -S(O)2NH2-, -S(O)0-2R10, terc-butildimetilsililmetil, -C(O)R12 i i gde su supstituenti na atomu azota supstituisanog heteroprstena, kad ih ima, izabrani iz grupe koju cine nizi alkil, nizi alkoksi, -C(O)OR5, -C(O)R5, OH, NR10R11(nizi alkil)-, NR10R11(nizi alkoksi)-, --S(O)2NH2- i 2-(trimetilsilil)etoksimetil; -C(O)B; ili gde je k, 1 ili 2; D je B'-(CH2),C(O)-, gde je m, 1, 2, 3, 4 ili 5; B'-(CH2)q, gde je q, 2, 3, 4, 5 ili 6; B'-(CH2)e-Z-(CH2)r-, gde je Z, -O-, -C(O)-, fenilen, -NR8- ili -S(O)0-2, e je 0, 1, 2, 3, 4 ili 5 i r je 1, 2, 3, 4 ili 5, uz uslov da je suma e i r 1, 2, 3, 4, 5 ili 6; B'-(C2-C6alkenilen)-; B'-(C4-C6alkadienilen)-; B'-(CH2)t-Z-(C2-C6alkenilen)-, gde je Z kao sto je prethodno definisano, i gde je t, 0, 1, 2 ili 3 uz uslov da je zbir t i broja ugljenikovih atoma u alkilenskom lancu: 2, 3, 4, 5 ili 6; B'-(CH2)f-V-(CH2)g-, gde je V, C3-C6cikloalkilen, f je 1, 2, 3, 4 ili 5 i g je 0, 1, 2, 3, 4 ili 5 uz uslov da je suma f i g 1, 2, 3, 4, 5 ili 6; B'-(CH2)t-V-(C2-C6alkenilen)- ili B'-(C2-C6alkenilen)-V-(CH2)t, gde su V i t kao sto je prethodno definisano, uz uslov da je suma t i broja ugljenikovih atoma u alkenilenskom lancu 2, 3, 4, 5 ili 6; B'-(CH2)a-Z-(CH2)b-V-(CH2)d gde su Z i V kao sto je prethodno definisano i a, b i d su nezavisno 0, 1, 2, 3, 4, 5 ili 6, uz uslov da je suma a, b i d 0, 1, 2, 3, 4, 5 ili 6; T-(CH2)s-, gde je T, cikloalkil od 3-6 ugljenikova atoma i s je 1, 2, 3, 4, 5 ili 6; ili naftilmetil, heteroarilmetil ili W-supstituisan heteroarilmetil, gde su heteroaril i W kao sto je prethodno definisano; B je B' je naftil, heteroaril ili W-supstituisan heteroaril, gde je heteroaril kao sto je prethodno definisan, ili R je vodonik, fluoro, C1-C15alkil, C1-C15alkenil, C1-C15alkinil ili B-
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US99548892A | 1992-12-23 | 1992-12-23 |
Publications (2)
Publication Number | Publication Date |
---|---|
YU80293A YU80293A (sh) | 1997-12-05 |
YU49060B true YU49060B (sh) | 2003-08-29 |
Family
ID=25541876
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
YU80293A YU49060B (sh) | 1992-12-23 | 1993-12-21 | FARMACEUTSKE KOMPOZICIJE KOJE SADRŽE INHIBITOR BIOSINTEZE HOLESTEROLA I INHIBITIR APSORPCIJE Гџ-LAKTAM HOLESTEROLA |
Country Status (32)
Country | Link |
---|---|
US (1) | US5661145A (sh) |
EP (1) | EP0675714B1 (sh) |
JP (1) | JP3992728B2 (sh) |
KR (1) | KR100306936B1 (sh) |
CN (1) | CN1090479C (sh) |
AT (1) | ATE175872T1 (sh) |
AU (1) | AU680864B2 (sh) |
CA (1) | CA2152351C (sh) |
CZ (1) | CZ287125B6 (sh) |
DE (1) | DE69323213T2 (sh) |
DK (1) | DK0675714T3 (sh) |
EE (1) | EE03383B1 (sh) |
ES (1) | ES2128552T3 (sh) |
FI (1) | FI952916A0 (sh) |
GR (1) | GR3029405T3 (sh) |
HR (1) | HRP931515B1 (sh) |
HU (1) | HU221724B1 (sh) |
IL (1) | IL108112A (sh) |
LT (1) | LT3300B (sh) |
LV (1) | LV10919B (sh) |
MX (1) | MX9308053A (sh) |
MY (1) | MY109538A (sh) |
NO (1) | NO311325B1 (sh) |
NZ (1) | NZ259790A (sh) |
PL (1) | PL174128B1 (sh) |
SG (1) | SG45147A1 (sh) |
SI (1) | SI9300677A (sh) |
SK (1) | SK281173B6 (sh) |
TW (1) | TW319698B (sh) |
WO (1) | WO1994014433A1 (sh) |
YU (1) | YU49060B (sh) |
ZA (1) | ZA939552B (sh) |
Families Citing this family (81)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5631365A (en) | 1993-09-21 | 1997-05-20 | Schering Corporation | Hydroxy-substituted azetidinone compounds useful as hypocholesterolemic agents |
CA2200436A1 (en) * | 1994-09-20 | 1996-04-04 | Pfizer Inc. | Combination therapy for hypercholesterolemia |
US5624920A (en) * | 1994-11-18 | 1997-04-29 | Schering Corporation | Sulfur-substituted azetidinone compounds useful as hypocholesterolemic agents |
US5633246A (en) * | 1994-11-18 | 1997-05-27 | Schering Corporation | Sulfur-substituted azetidinone compounds useful as hypocholesterolemic agents |
US5656624A (en) * | 1994-12-21 | 1997-08-12 | Schering Corporation | 4-[(heterocycloalkyl or heteroaromatic)-substituted phenyl]-2-azetidinones useful as hypolipidemic agents |
CN1217656C (zh) | 1995-11-02 | 2005-09-07 | 沃尼尔·朗伯公司 | 用于调节脂浓度的方法和药物组合物 |
US20030153541A1 (en) * | 1997-10-31 | 2003-08-14 | Robert Dudley | Novel anticholesterol compositions and method for using same |
SI20109A (sl) * | 1998-12-16 | 2000-06-30 | LEK, tovarna farmacevtskih in kemi�nih izdelkov, d.d. | Stabilna farmacevtska formulacija |
AU4343500A (en) | 1999-04-16 | 2000-11-02 | Schering Corporation | Use of azetidinone compounds |
WO2001074420A1 (fr) * | 2000-04-05 | 2001-10-11 | Toray Industries, Inc. | Adsorbants pour proteines de la famille hmg et colonne de purification de liquide organique |
US6979462B1 (en) * | 2000-10-03 | 2005-12-27 | Mutual Pharmaceutical Co., Inc. | Stabilization of solid drug formulations |
US6584357B1 (en) * | 2000-10-17 | 2003-06-24 | Sony Corporation | Method and system for forming an acoustic signal from neural timing difference data |
US6982251B2 (en) | 2000-12-20 | 2006-01-03 | Schering Corporation | Substituted 2-azetidinones useful as hypocholesterolemic agents |
CN1915429B (zh) * | 2001-01-26 | 2010-12-15 | 先灵公司 | 过氧化物酶体增殖物激活受体(ppar)活化剂和甾醇吸收抑制剂的组合药 |
EP1911462A3 (en) | 2001-01-26 | 2011-11-30 | Schering Corporation | Compositions comprising a sterol absorption inhibitor |
CN1275949C (zh) | 2001-03-28 | 2006-09-20 | 先灵公司 | 2-吖丁啶酮中间体化合物的对映体选择性合成 |
BR0212907A (pt) * | 2001-09-21 | 2004-10-13 | Schering Corp | Métodos para tratamento ou prevenção de inflamação vascular usando inibidor(es) da absorção de esteróis |
ES2272776T3 (es) * | 2001-09-21 | 2007-05-01 | Schering Corporation | Tratamiento de xantomas con derivados de azetidinona como inhibidores de la absorcion de esterol. |
US6984645B2 (en) | 2001-11-16 | 2006-01-10 | Bristol-Myers Squibb Company | Dual inhibitors of adipocyte fatty acid binding protein and keratinocyte fatty acid binding protein |
US20030204096A1 (en) * | 2002-03-25 | 2003-10-30 | Schering Corporation | Enantioselective synthesis of azetidinone intermediate compounds |
GB0215579D0 (en) * | 2002-07-05 | 2002-08-14 | Astrazeneca Ab | Chemical compounds |
US7135556B2 (en) * | 2002-07-19 | 2006-11-14 | Schering Corporation | NPC1L1 (NPC3) and methods of use thereof |
AR040588A1 (es) | 2002-07-26 | 2005-04-13 | Schering Corp | Formulacion farmaceutica que comprende un inhibidor de la absorcion del colesterol y un inhibidor de una hmg- co a reductasa |
JP4654035B2 (ja) | 2002-11-05 | 2011-03-16 | グラクソスミスクライン・リミテッド・ライアビリティ・カンパニー | 抗菌剤 |
EP1810971B1 (en) * | 2003-03-07 | 2013-12-25 | Merck Sharp & Dohme Corp. | Substituted azetidinone compounds, formulations and uses thereof for the treatment of hypercholesterolemia |
CN1756756A (zh) * | 2003-03-07 | 2006-04-05 | 先灵公司 | 取代的2-吖丁啶酮化合物、其制剂及其治疗高胆甾醇血症的用途 |
CA2517573C (en) * | 2003-03-07 | 2011-12-06 | Schering Corporation | Substituted azetidinone compounds, formulations and uses thereof for the treatment of hypercholesterolemia |
ES2311806T3 (es) | 2003-03-07 | 2009-02-16 | Schering Corporation | Compuesto de azetidinona sustituidos, fornulaciones y usos de los mismos para el tratamiento de hipercolesterolemia. |
JP2005015434A (ja) * | 2003-06-27 | 2005-01-20 | Kotobuki Seiyaku Kk | 血清コレステロール低下剤或はアテローム性硬化症の予防又は治療剤 |
US20060089374A1 (en) * | 2003-07-17 | 2006-04-27 | Glenn Cornett | Enantiomeric compositions of cicletanine, alone and in combination with other agents, for the treatment of disease |
WO2005021039A1 (en) * | 2003-08-29 | 2005-03-10 | Cotherix, Inc. | Combination of cicletanine and an oral antidiabetic and/or blood lipid-lowering agent for treating diabetes and metabolic syndrome |
US7371759B2 (en) | 2003-09-25 | 2008-05-13 | Bristol-Myers Squibb Company | HMG-CoA reductase inhibitors and method |
EP1918000A2 (en) | 2003-11-05 | 2008-05-07 | Schering Corporation | Combinations of lipid modulating agents and substituted azetidinones and treatments for vascular conditions |
US7420059B2 (en) | 2003-11-20 | 2008-09-02 | Bristol-Myers Squibb Company | HMG-CoA reductase inhibitors and method |
GB0329778D0 (en) * | 2003-12-23 | 2004-01-28 | Astrazeneca Ab | Chemical compounds |
AU2004308332B2 (en) * | 2003-12-23 | 2008-04-10 | Merck Sharp & Dohme Corp. | Anti-hypercholesterolemic compounds |
DE602004029715D1 (de) | 2003-12-23 | 2010-12-02 | Astrazeneca Ab | Diphenylazetidinonderivate mit die cholesterinabsorption hemmender wirkung |
JP4590417B2 (ja) * | 2004-01-16 | 2010-12-01 | メルク・シャープ・エンド・ドーム・コーポレイション | Npc1l1(npc3)およびこのリガンドの同定方法 |
MX2007000030A (es) * | 2004-07-01 | 2007-03-07 | Schering Corp | Derivados de piperidina como antagonistas de neuroquinina-1. |
US7572805B2 (en) | 2004-07-14 | 2009-08-11 | Bristol-Myers Squibb Company | Pyrrolo(oxo)isoquinolines as 5HT ligands |
US20060046996A1 (en) | 2004-08-31 | 2006-03-02 | Kowa Co., Ltd. | Method for treating hyperlipidemia |
US20060154959A1 (en) * | 2005-01-13 | 2006-07-13 | Navitas Pharma | Combination therapies of cicletanine and carvedilol |
JP2008514718A (ja) * | 2004-09-29 | 2008-05-08 | シェーリング コーポレイション | 置換アゼチドノンおよびcb1アンタゴニストの組み合わせ |
US7517991B2 (en) | 2004-10-12 | 2009-04-14 | Bristol-Myers Squibb Company | N-sulfonylpiperidine cannabinoid receptor 1 antagonists |
WO2006076598A2 (en) | 2005-01-12 | 2006-07-20 | Bristol-Myers Squibb Company | Bicyclic heterocycles as cannabinoid receptor modulators |
WO2006076569A2 (en) | 2005-01-12 | 2006-07-20 | Bristol-Myers Squibb Company | Bicyclic heterocycles as cannabinoid receptor modulators |
US7368458B2 (en) | 2005-01-12 | 2008-05-06 | Bristol-Myers Squibb Company | Bicyclic heterocycles as cannabinoid receptor modulators |
US20080096915A1 (en) * | 2005-01-13 | 2008-04-24 | Greenberg Traurig LLP | Compositions for the treatment of metabolic disorders |
US20070141174A1 (en) * | 2005-01-13 | 2007-06-21 | Navitas Pharma, Inc. | Enantiomeric compositions of cicletanine, in combination with other agents, for the treatment of hypertension |
US20060160850A1 (en) | 2005-01-18 | 2006-07-20 | Chongqing Sun | Bicyclic heterocycles as cannabinoid receptor modulators |
WO2006086464A2 (en) | 2005-02-10 | 2006-08-17 | Bristol-Myers Squibb Company | Dihydroquinazolinones as 5ht modulators |
US7317012B2 (en) | 2005-06-17 | 2008-01-08 | Bristol-Myers Squibb Company | Bicyclic heterocycles as cannabinoind-1 receptor modulators |
US7629342B2 (en) | 2005-06-17 | 2009-12-08 | Bristol-Myers Squibb Company | Azabicyclic heterocycles as cannabinoid receptor modulators |
US7452892B2 (en) | 2005-06-17 | 2008-11-18 | Bristol-Myers Squibb Company | Triazolopyrimidine cannabinoid receptor 1 antagonists |
US7572808B2 (en) | 2005-06-17 | 2009-08-11 | Bristol-Myers Squibb Company | Triazolopyridine cannabinoid receptor 1 antagonists |
US7632837B2 (en) | 2005-06-17 | 2009-12-15 | Bristol-Myers Squibb Company | Bicyclic heterocycles as cannabinoid-1 receptor modulators |
KR20080021082A (ko) | 2005-06-20 | 2008-03-06 | 쉐링 코포레이션 | 히스타민 h3 길항제로서 유용한 피페리딘 유도체 |
UY29607A1 (es) * | 2005-06-20 | 2007-01-31 | Astrazeneca Ab | Compuestos quimicos |
AR057383A1 (es) * | 2005-06-22 | 2007-12-05 | Astrazeneca Ab | Compuestos quimicos derivados de 2-azetidinona, formulacion farmaceutica y un proceso de preparacion del compuesto |
MY148538A (en) * | 2005-06-22 | 2013-04-30 | Astrazeneca Ab | Novel 2-azetidinone derivatives as cholesterol absorption inhibitors for the treatment of hyperlipidaemic conditions |
AR057380A1 (es) * | 2005-06-22 | 2007-11-28 | Astrazeneca Ab | Compuestos quimicos derivados de 2-azetidinona y uso terapeutico de los mismos |
AR054482A1 (es) * | 2005-06-22 | 2007-06-27 | Astrazeneca Ab | Derivados de azetidinona para el tratamiento de hiperlipidemias |
SA06270191B1 (ar) * | 2005-06-22 | 2010-03-29 | استرازينيكا ايه بي | مشتقات من 2- أزيتيدينون جديدة باعتبارها مثبطات لامتصاص الكوليسترول لعلاج حالات فرط نسبة الدهون في الدم |
US7795436B2 (en) | 2005-08-24 | 2010-09-14 | Bristol-Myers Squibb Company | Substituted tricyclic heterocycles as serotonin receptor agonists and antagonists |
AR056155A1 (es) | 2005-10-26 | 2007-09-19 | Bristol Myers Squibb Co | Antagonistas del receptor 1 de la hormona de concentracion de melanina no basica |
US20070105817A1 (en) * | 2005-11-09 | 2007-05-10 | Jim Page | Use of cicletanine and other furopyridines for treatment of systolic-predominant hypertension, isolated systolic hypertension, elevated pulse pressure, and general hypertension |
WO2007075702A2 (en) * | 2005-12-21 | 2007-07-05 | Schering Corporation | Treatment of nonalcoholic fatty liver disease using cholesterol lowering agents and h3 receptor antagonist/inverse agonist |
US7553836B2 (en) | 2006-02-06 | 2009-06-30 | Bristol-Myers Squibb Company | Melanin concentrating hormone receptor-1 antagonists |
EP1986489A2 (en) | 2006-02-24 | 2008-11-05 | Schering Corporation | Npc1l1 orthologues |
TW200811098A (en) | 2006-04-27 | 2008-03-01 | Astrazeneca Ab | Chemical compounds |
US20070275052A1 (en) * | 2006-05-24 | 2007-11-29 | Glenmark Pharmaceuticals Limited | Pharmaceutical compositions containing sterol inhibitors |
CA2661404A1 (en) * | 2006-09-05 | 2008-03-13 | Schering Corporation | Pharmaceutical combinations for lipid management and in the treatment of atherosclerosis and hepatic steatosis |
CA2674367A1 (en) * | 2007-01-03 | 2008-07-17 | Glenn V. Cornett | Cicletanine and pkc inhibitors in the treatment of pulmonary and cardiac disorders |
US20090011994A1 (en) | 2007-07-06 | 2009-01-08 | Bristol-Myers Squibb Company | Non-basic melanin concentrating hormone receptor-1 antagonists and methods |
PE20091928A1 (es) | 2008-05-29 | 2009-12-31 | Bristol Myers Squibb Co | Tienopirimidinas hidroxisustituidas como antagonistas de receptor-1 de hormona concentradora de melanina no basicos |
US20100092479A1 (en) * | 2008-08-18 | 2010-04-15 | Combinatorx (Singapore) Pte. Ltd. | Compositions and methods for treatment of viral diseases |
JP2012522015A (ja) | 2009-03-27 | 2012-09-20 | ブリストル−マイヤーズ スクイブ カンパニー | Dpp−iv阻害剤を用いて主要有害心血管事象を予防する方法 |
WO2014039412A1 (en) | 2012-09-05 | 2014-03-13 | Bristol-Myers Squibb Company | Pyrrolone or pyrrolidinone melanin concentrating hormone receptor-1 antagonists |
US9586900B2 (en) | 2012-09-05 | 2017-03-07 | Bristol-Myers Squibb Company | Pyrrolone or pyrrolidinone melanin concentrating hormone receptor-1 antagonists |
SG11202100417RA (en) | 2018-07-19 | 2021-02-25 | Astrazeneca Ab | Methods of treating hfpef employing dapagliflozin and compositions comprising the same |
AU2022291768A1 (en) | 2021-06-16 | 2023-11-30 | Celgene Corporation | Azetidinyl compounds comprising a carboxylic acid group for the treatment of neurodegenerative diseases |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4680391A (en) * | 1983-12-01 | 1987-07-14 | Merck & Co., Inc. | Substituted azetidinones as anti-inflammatory and antidegenerative agents |
US4983597A (en) * | 1989-08-31 | 1991-01-08 | Merck & Co., Inc. | Beta-lactams as anticholesterolemic agents |
US5120729A (en) * | 1990-06-20 | 1992-06-09 | Merck & Co., Inc. | Beta-lactams as antihypercholesterolemics |
US5085473A (en) * | 1990-10-09 | 1992-02-04 | Yuhe Yang | Air actuated car curtain device |
IL102582A0 (en) | 1991-07-23 | 1993-01-14 | Schering Corp | Substituted beta-lactam compounds useful as hypocholesterolemic agents and processes for the preparation thereof |
WO2013111017A2 (en) | 2012-01-26 | 2013-08-01 | Intralot S.A. - Integrated Lottery Systems And Services | Methods and systems for dispensing |
-
1993
- 1993-12-03 LT LTIP1514A patent/LT3300B/lt not_active IP Right Cessation
- 1993-12-13 MX MX9308053A patent/MX9308053A/es unknown
- 1993-12-21 AT AT94904854T patent/ATE175872T1/de active
- 1993-12-21 DE DE69323213T patent/DE69323213T2/de not_active Expired - Lifetime
- 1993-12-21 IL IL10811293A patent/IL108112A/en not_active IP Right Cessation
- 1993-12-21 ES ES94904854T patent/ES2128552T3/es not_active Expired - Lifetime
- 1993-12-21 DK DK94904854T patent/DK0675714T3/da active
- 1993-12-21 EP EP94904854A patent/EP0675714B1/en not_active Expired - Lifetime
- 1993-12-21 CA CA002152351A patent/CA2152351C/en not_active Expired - Fee Related
- 1993-12-21 HU HU9501854A patent/HU221724B1/hu not_active IP Right Cessation
- 1993-12-21 NZ NZ259790A patent/NZ259790A/en not_active IP Right Cessation
- 1993-12-21 US US08/454,348 patent/US5661145A/en not_active Expired - Lifetime
- 1993-12-21 JP JP51530594A patent/JP3992728B2/ja not_active Expired - Fee Related
- 1993-12-21 ZA ZA939552A patent/ZA939552B/xx unknown
- 1993-12-21 YU YU80293A patent/YU49060B/sh unknown
- 1993-12-21 WO PCT/US1993/012291 patent/WO1994014433A1/en active IP Right Grant
- 1993-12-21 SG SG1996000543A patent/SG45147A1/en unknown
- 1993-12-21 SK SK783-95A patent/SK281173B6/sk not_active IP Right Cessation
- 1993-12-21 CZ CZ19951643A patent/CZ287125B6/cs not_active IP Right Cessation
- 1993-12-21 MY MYPI93002792A patent/MY109538A/en unknown
- 1993-12-21 AU AU58720/94A patent/AU680864B2/en not_active Ceased
- 1993-12-21 KR KR1019950702608A patent/KR100306936B1/ko not_active IP Right Cessation
- 1993-12-21 TW TW082110824A patent/TW319698B/zh not_active IP Right Cessation
- 1993-12-21 PL PL93309636A patent/PL174128B1/pl not_active IP Right Cessation
- 1993-12-22 SI SI9300677A patent/SI9300677A/sl not_active IP Right Cessation
- 1993-12-22 CN CN93112663A patent/CN1090479C/zh not_active Expired - Fee Related
- 1993-12-22 HR HR07/995,488A patent/HRP931515B1/xx not_active IP Right Cessation
-
1994
- 1994-11-23 EE EE9400341A patent/EE03383B1/xx not_active IP Right Cessation
-
1995
- 1995-06-14 FI FI952916A patent/FI952916A0/fi unknown
- 1995-06-22 LV LVP-95-189A patent/LV10919B/en unknown
- 1995-06-23 NO NO19952529A patent/NO311325B1/no not_active IP Right Cessation
-
1999
- 1999-02-16 GR GR990400487T patent/GR3029405T3/el unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
YU49060B (sh) | FARMACEUTSKE KOMPOZICIJE KOJE SADRŽE INHIBITOR BIOSINTEZE HOLESTEROLA I INHIBITIR APSORPCIJE Гџ-LAKTAM HOLESTEROLA | |
AU6969994A (en) | A pharmaceutical composition for the intranasal administration of hydroxocobalamin | |
BG103190A (en) | Substituted pyrimidine derivatives and their pharmaceutical application | |
YU27199A (sh) | Ziprasidon formulacije | |
EP0646007A4 (sh) | ||
AU4923093A (en) | Inhibitors of metazoan parasite proteases | |
ZA986673B (en) | Use of a combination of an inhibitor of converting enzyme and a diuretic for treating microcirculatory disorders | |
GB9509321D0 (en) | Methods of and substances for inhibiting oxidative enzymes | |
IL125821A0 (en) | A pharmaceutical composition containing dehydroepiandrosterone and aromatase inhibitors and use thereof | |
WO1994005296A3 (en) | Use of cytochrome p450 inhibitors for inhibiting the metabolism of nitrogen substituted acridine | |
IL111917A0 (en) | A pharmaceutical composition containing a parasympathomimetic compound and a parasympatholytic compound | |
EP0674521A4 (en) | METHOD FOR TREATING CHRONIC PROSTATITIS WITH 17-BETA-N MONO SUBSTITUTED CARBAMOYL-4-AZA-5 ALPHA-ANDROST-1-EN-3-ONES. | |
AU7941294A (en) | Composition for the treatment or prevention of herpes | |
SI0912568T1 (en) | Imidazopyridines | |
AU5625194A (en) | Rectal flunisolide compositions for treating inflammatory intestinal disorders | |
UA41376C2 (uk) | ФАРМАЦЕВТИЧНА КОМПОЗИЦІЯ ТА СПОСІБ ЛІКУВАННЯ АНДРОГЕННОЇ АЛОПЕЦІЇ ІНГІБІТОРАМИ 5-<font face="Symbol">a</font>-РЕДУКТАЗИ | |
CA2135712A1 (en) | The synergistic activity of glutaraldehyde in the presence of oxidants |